$NTRB
NutriBand Inc. Stock $ntrb

$ntrb Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024048363 Filed on May 31, 2024

Income Statement

Concept	2024 Q2
Revenue	$408.5K
YoY Change	-14.34%
Cost Of Revenue	$243.7K
YoY Change	-4.28%
Gross Profit	$164.8K
YoY Change	-25.87%
Gross Profit Margin	40.34%
Selling, General & Admin	$1.080M
YoY Change	28.58%
% of Gross Profit	655.23%
Research & Development	$974.5K
YoY Change	143.37%
% of Gross Profit	591.39%
Depreciation & Amortization	$69.10K
YoY Change	-8.11%
% of Gross Profit	41.93%
Operating Expenses	$2.054M
YoY Change	65.64%
Operating Profit	-$1.889M
YoY Change	85.63%
Interest Expense	$8.618K
YoY Change	225.21%
% of Operating Profit
Other Income/Expense, Net	-$8.600K
YoY Change	-424.65%
Pretax Income	-$1.898M
YoY Change	86.96%
Income Tax
% Of Pretax Income
Net Earnings	-$1.898M
YoY Change	86.96%
Net Earnings / Revenue	-464.61%
Basic Earnings Per Share	-$0.21
Diluted Earnings Per Share	-$0.21
COMMON SHARES
Basic Shares Outstanding	10.97M shares
Diluted Shares Outstanding	9.160M shares

Balance Sheet

Concept	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.348M
YoY Change	553.15%
Cash & Equivalents	$8.348M
Short-Term Investments
Other Short-Term Assets	$128.6K
YoY Change	-65.19%
Inventory	$168.5K
Prepaid Expenses	$128.6K
Receivables	$85.14K
Other Receivables	$0.00
Total Short-Term Assets	$8.730M
YoY Change	337.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$740.3K
YoY Change	-13.26%
Goodwill	$5.022M
YoY Change	0.0%
Intangibles	$639.0K
YoY Change	-15.04%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$6.425M
YoY Change	-3.86%
TOTAL ASSETS
Total Short-Term Assets	$8.730M
Total Long-Term Assets	$6.425M
Total Assets	$15.15M
YoY Change	74.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$994.1K
YoY Change	82.82%
Accrued Expenses	$25.99K
YoY Change	-18.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due	$127.4K
YoY Change	539.34%
Total Short-Term Liabilities	$1.417M
YoY Change	80.63%
LONG-TERM LIABILITIES
Long-Term Debt	$374.5K
YoY Change	157.52%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$374.5K
YoY Change	118.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.417M
Total Long-Term Liabilities	$374.5K
Total Liabilities	$1.791M
YoY Change	87.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$29.88M
YoY Change	27.09%
Common Stock	$10.96K
YoY Change	39.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$32.64K
YoY Change	0.0%
Treasury Stock Shares
Shareholders Equity	$13.36M
YoY Change
Total Liabilities & Shareholders Equity	$15.15M
YoY Change	74.68%

Cashflow Statement

Concept	2024 Q2
OPERATING ACTIVITIES
Net Income	-$1.898M
YoY Change	86.96%
Depreciation, Depletion And Amortization	$69.10K
YoY Change	-8.11%
Cash From Operating Activities	-$833.9K
YoY Change	11.21%
INVESTING ACTIVITIES
Capital Expenditures	$6.195K
YoY Change	136.09%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$6.195K
YoY Change	136.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$8.695M
YoY Change	19169.37%
NET CHANGE
Cash From Operating Activities	-$833.9K
Cash From Investing Activities	-$6.195K
Cash From Financing Activities	$8.695M
Net Change In Cash	$7.855M
YoY Change	-1210.43%
FREE CASH FLOW
Cash From Operating Activities	-$833.9K
Capital Expenditures	$6.195K
Free Cash Flow	-$840.1K
YoY Change	11.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7833150	shares
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9159869	shares
CY2024Q2	dei	Document Type DocumentType	10-Q
CY2024Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q2	dei	Document Period End Date DocumentPeriodEndDate	2024-04-30
CY2024Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q2	dei	Entity File Number EntityFileNumber	000-55654
CY2024Q2	dei	Entity Registrant Name EntityRegistrantName	NUTRIBAND INC.
CY2024Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-1118176
CY2024Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	121 South Orange Ave
CY2024Q2	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1500
CY2024Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2024Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32801
CY2024Q2	dei	City Area Code CityAreaCode	(407)
CY2024Q2	dei	Local Phone Number LocalPhoneNumber	377-6695
CY2024Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2024Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q2	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q2	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11036100	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8347740	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	492942	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	85144	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	148649	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	168505	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	168605	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	128551	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	211667	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	8729940	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	1021863	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	740305	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	774924	usd
CY2024Q2	us-gaap	Goodwill Goodwill	5021713	usd
CY2024Q1	us-gaap	Goodwill Goodwill	5021713	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23529	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31374	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	638993	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	667280	usd
CY2024Q2	us-gaap	Assets Assets	15154480	usd
CY2024Q1	us-gaap	Assets Assets	7517154	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	994106	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	680132	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	269345	usd
CY2024Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	157502	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	25988	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	34276	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	127419	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	127183	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1416858	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	999093	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	74509	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	79826	usd
CY2024Q2	us-gaap	Liabilities Liabilities	1791367	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1078919	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	291666666	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	291666666	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10969870	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10969870	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8869870	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8869870	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	10960	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	8860	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43263194	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	34442339	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-304	usd
CY2024Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10000	shares
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	10000	shares
CY2024Q2	us-gaap	Treasury Stock Value TreasuryStockValue	32641	usd
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	32641	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-29878096	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-27980019	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	13363113	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6438235	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15154480	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7517154	usd
CY2024Q2	us-gaap	Revenues Revenues	408532	usd
CY2023Q2	us-gaap	Revenues Revenues	476932	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	243746	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	254648	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	974535	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	400430	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1079728	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	839732	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	2298009	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	1494810	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1889477	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1017878	usd
CY2024Q2	us-gaap	Interest Income Other InterestIncomeOther	18	usd
CY2023Q2	us-gaap	Interest Income Other InterestIncomeOther	5815	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	8618	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	3166	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8600	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2649	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1898077	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1015229	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1898077	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1015229	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9159869	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7833150	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	6438235	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	422955	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8400000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1898077	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	13363113	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	8572990	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	87090	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	75030	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1015229	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7719881	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1898077	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1015229	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	69101	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	75201	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	7845	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	7845	usd
CY2023Q2	ntrb	Stockbased Compensationwarrants StockbasedCompensationwarrants	87090	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	422955	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	75030	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-63505	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	51596	usd
CY2024Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-84631	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	3354	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1415	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-47838	usd
CY2024Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	111843	usd
CY2023Q2	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	25794	usd
CY2024Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8288	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7557	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	313974	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9074	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-833926	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-749864	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6195	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2624	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6195	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2624	usd
CY2024Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	300000	usd
CY2023Q2	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	50000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8400000	usd
CY2024Q2	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5081	usd
CY2023Q2	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4877	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8694919	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45123	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	7854798	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-707365	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	492942	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1985440	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8347740	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1278075	usd
CY2024Q2	us-gaap	Interest Paid Net InterestPaidNet	611	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	1725	usd
CY2018Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	2250000	usd
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	250000	shares
CY2018Q3	ntrb	Royalty Percentage RoyaltyPercentage	0.06	pure
CY2024Q2	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022.
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8347740	usd
CY2024Q2	ntrb	Working Capital WorkingCapital	7313082	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-1898077	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-833926	usd
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2000000	usd
CY2023Q3	us-gaap	Line Of Credit LineOfCredit	5000000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8400000	usd
CY2024Q2	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i><span style="text-decoration:underline">Use of Estimates </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p>
CY2024Q2	us-gaap	Revenues Revenues	408532	usd
CY2023Q2	us-gaap	Revenues Revenues	476932	usd
CY2024Q2	us-gaap	Revenues Revenues	408532	usd
CY2023Q2	us-gaap	Revenues Revenues	476932	usd
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	7879000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1200	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2024Q2	us-gaap	Accounts Receivable Fair Value Disclosure AccountsReceivableFairValueDisclosure	106528	usd
CY2024Q2	ntrb	Loan Bears Interest Percentage LoanBearsInterestPercentage	0.10	pure
CY2024Q2	us-gaap	Inventory Net InventoryNet	168505	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	27447	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	26751	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	114307	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	168605	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	8707	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	134691	usd
CY2024Q2	ntrb	Estimated Useful Live EstimatedUsefulLive	P10Y
CY2024Q1	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	3302478	usd
CY2024Q2	us-gaap	Goodwill Goodwill	5021713	usd
CY2024Q1	us-gaap	Goodwill Goodwill	5021713	usd
CY2024Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	6747873	shares
CY2023Q2	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	1783373	shares
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1462812	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1456617	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	722507	usd
CY2024Q1	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	681693	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	740305	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	774924	usd
CY2024Q2	us-gaap	Depreciation Depreciation	40814	usd
CY2023Q2	us-gaap	Depreciation Depreciation	46914	usd
CY2024Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	30242	usd
CY2023Q2	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	36179	usd
CY2024Q2	us-gaap	Line Of Credit Facility Expiration Date1 LineOfCreditFacilityExpirationDate1	2028-10-16
CY2024Q2	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.05	pure
CY2024Q2	us-gaap	Notes Payable NotesPayable	81290	usd
CY2024Q2	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	16331	usd
CY2022Q2	us-gaap	Line Of Credit LineOfCredit	32274	usd
CY2022Q2	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	22795	usd
CY2022Q2	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0295	pure
CY2022Q2	us-gaap	Line Of Credit Facility Periodic Payment LineOfCreditFacilityPeriodicPayment	410	usd
CY2024Q2	us-gaap	Line Of Credit Facility Maximum Amount Outstanding During Period LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod	4560	usd
CY2024	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	15232	usd
CY2023Q3	us-gaap	Line Of Credit Facility Capacity Available For Trade Purchases LineOfCreditFacilityCapacityAvailableForTradePurchases	5000000	usd
CY2024Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.07	pure
CY2023Q1	ntrb	Line Of Credit Facility Converted LineOfCreditFacilityConverted	2000000	usd
CY2023	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	53476	usd
CY2023	ntrb	Line Of Credit Facility Common Stock LineOfCreditFacilityCommonStock	1026520	shares
CY2024Q2	ntrb	Fair Value Of Common Stock FairValueOfCommonStock	2554423	usd
CY2024Q2	us-gaap	Advance Rent AdvanceRent	300000	usd
CY2024Q2	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	300000	usd
CY2024Q1	us-gaap	Notes And Loans Payable NotesAndLoansPayable	106528	usd
CY2024Q1	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.10	pure
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	2578	usd
CY2023Q4	us-gaap	Interest Expense Debt InterestExpenseDebt	3166	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1131500	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1131500	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	492507	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	464220	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	638993	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	667280	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	28287	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	28287	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	84863	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	113148	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	113148	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	113148	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	94226	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	120460	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	638993	usd
CY2024Q2	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	390000	shares
CY2024Q2	ntrb	Options Vest And Expire Term OptionsVestAndExpireTerm	P3Y
CY2024Q2	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	422955	usd
CY2024Q2	us-gaap	Investments Investments	7120000	usd
CY2024Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	1780000	usd
CY2024Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3560000	shares
CY2024Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	6.43
CY2023Q2	ntrb	Options Vest And Expire Term OptionsVestAndExpireTerm	P3Y
CY2024Q2	ntrb	Common Stock Of Description CommonStockOfDescription	the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.
CY2024Q2	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	10000	shares
CY2024Q2	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	32641	usd
CY2024Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	8400000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	2	shares
CY2023Q2	us-gaap	Option Indexed To Issuers Equity Shares OptionIndexedToIssuersEquityShares	10000	shares
CY2023Q2	us-gaap	Redeemable Noncontrolling Interest Equity Other Carrying Amount RedeemableNoncontrollingInterestEquityOtherCarryingAmount	32641	usd
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	30000	shares
CY2023Q1	ntrb	Options Vest Expire Year OptionsVestExpireYear	P5Y
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	145833	shares
CY2024Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	1.93
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	242840	usd
CY2024Q2	ntrb	Common Stock Shares Issued Warrants CommonStockSharesIssuedWarrants	4200000	shares
CY2024Q2	ntrb	Options Vest Expire Year OptionsVestExpireYear	P5Y
CY2024Q2	ntrb	Schedule Of Additional Relating Warrants Outstanding ScheduleOfAdditionalRelatingWarrantsOutstanding	The following table summarizes additional information relating to the warrants outstanding as of April 30, 2024:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: left">Range of Exercise<br/> Prices</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number<br/> Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life(Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Outstanding</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number<br/> Exercisable</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Exercisable</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">4.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">30,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">4.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">30,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">4.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,282,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.68</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,282,205</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6.43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">$</td><td style="text-align: right">1.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.93</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">233,125</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">7.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right">3.77</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">7.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">7.50</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,483,038</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">5,483,038</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">233,125</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p>
CY2021Q4	us-gaap	Shares Issued SharesIssued	408333	shares
CY2022Q1	ntrb	Additional Shares Reserved AdditionalSharesReserved	233333	shares
CY2023Q1	ntrb	Additional Shares Reserved AdditionalSharesReserved	233333	shares
CY2021Q4	ntrb	Common Stock Reserved CommonStockReserved	408333	shares
CY2024Q1	ntrb	Shares Held In Companys Employee Stock Option Plan Before Amendment SharesHeldInCompanysEmployeeStockOptionPlanBeforeAmendment	875000	shares
CY2024Q1	ntrb	Shares Held In Companys Employee Stock Option Plan After Amendment SharesHeldInCompanysEmployeeStockOptionPlanAfterAmendment	1400000	shares
CY2024Q2	ntrb	Balance Shares Issuance Of Options BalanceSharesIssuanceOfOptions	135165	shares
CY2024Q2	ntrb	Expire Year ExpireYear	P3Y
CY2024Q2	us-gaap	Fair Value Option Ineligible Items Aggregate Carrying Amount FairValueOptionIneligibleItemsAggregateCarryingAmount	422955	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y6M
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9783	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0487	pure
CY2024	ntrb	Expire Year ExpireYear	P3Y
CY2024Q1	us-gaap	Fair Value Option Ineligible Items Aggregate Carrying Amount FairValueOptionIneligibleItemsAggregateCarryingAmount	499856	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y6M
CY2024Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2024Q2	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	408532	usd
CY2023Q2	us-gaap	Gain Loss On Sales Of Loans Net GainLossOnSalesOfLoansNet	476932	usd
CY2024Q2	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	164786	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	222284	usd
CY2024Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2054263	usd
CY2023Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1240162	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	69101	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold Depreciation And Amortization CostOfGoodsAndServicesSoldDepreciationAndAmortization	75201	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	408532	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	476932	usd
CY2024Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	740305	usd
CY2024Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	774924	usd
CY2024Q2	us-gaap	Other Assets OtherAssets	15154480	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	7516854	usd
CY2024Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022
CY2024Q2	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	250000	usd
CY2024Q2	ntrb	Percentage Of Net Income PercentageOfNetIncome	0.035	pure
CY2022Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	150000	usd
CY2024Q2	us-gaap	Other Commitments Description OtherCommitmentsDescription	the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system).
CY2024Q2	ntrb	Estimated Cost EstimatedCost	2500000	usd
CY2022Q1	us-gaap	Deposit Assets DepositAssets	250000	usd
CY2024Q2	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	2950998	usd
CY2024Q2	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	250000	usd
CY2024Q1	ntrb	Estimated Cost EstimatedCost	8100000	usd
CY2022Q1	ntrb	Warehouse Space WarehouseSpace	12000	pure
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3000	usd
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	94134	usd
CY2023Q3	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	106528	usd
CY2024Q1	us-gaap	Cash And Due From Banks CashAndDueFromBanks	118675	usd
CY2024Q2	us-gaap	Legal Fees LegalFees	500000	usd
CY2024Q2	us-gaap	Cash Cash	1000000	usd
CY2024Q2	ntrb	Stockbased Compensationwarrants StockbasedCompensationwarrants		usd
CY2023Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2024Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q2	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2024Q2	dei	Amendment Flag AmendmentFlag	false
CY2024Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-31
CY2024Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001676047

Files In Submission

Name	View Source	Status
0001213900-24-048363-index-headers.html	Edgar Link	pending
0001213900-24-048363-index.html	Edgar Link	pending
0001213900-24-048363.txt	Edgar Link	pending
0001213900-24-048363-xbrl.zip	Edgar Link	pending
ea0206964-10q_nutriband.htm	Edgar Link	pending
ea020696401ex31-1_nutriband.htm	Edgar Link	pending
ea020696401ex31-2_nutriband.htm	Edgar Link	pending
ea020696401ex32-1_nutriband.htm	Edgar Link	pending
ea020696401ex32-2_nutriband.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ntrb-20240430.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
ntrb-20240430_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ntrb-20240430_def.xml	Edgar Link	unprocessable
ntrb-20240430_lab.xml	Edgar Link	unprocessable
ntrb-20240430_pre.xml	Edgar Link	unprocessable
ea0206964-10q_nutriband_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NTRB
NutriBand Inc. Stock $ntrb

2024 Q2 Form 10-Q Financial Statement

#000121390024048363 Filed on May 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRB NutriBand Inc. Stock $ntrb

2024 Q2 Form 10-Q Financial Statement

#000121390024048363 Filed on May 31, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRB
NutriBand Inc. Stock $ntrb